Phase 2 N=45 Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Time to Disease Progression — 6.87 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Rosiglitazone Effect on Mitochondria and Lipoatrophy
HIV Infections
Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
Phase 2 N=35 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Dose Limiting Toxicity (DLT) for Phase I Patients — 0 patients
Phase 2 N=10 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 6 participants
Phase 2 N=86 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Laryngeal Verrucous Carcinoma
Primary: Progression-free Survival (PFS) — 105; 105 days — p=0.73
Phase 2 N=111 Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) — 77; 32; 2 Participants
Phase 2 N=51 Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Prostate Cancer
Primary: Observed Maximum Serum Leuprolide Concentration (Cmax) for Dose 1 and Dose 3 — 6.14; 9.66; 13.6; 5.36 ng/mL
Phase 2 N=35 Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Amyloidosis
Primary: Number of Participants With Disease Response — 20 Participants
Phase 2 N=180 Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults
Tuberculosis
Primary: Number of Subjects With Solicited Local Symptoms — 8; 3; 35; 33 Subjects
Phase 2 N=19 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Phase 2 N=269 A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine
Pain
Primary: Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6) — 4.37; 20.75; 8.95; 20.56 units on a scale…
Phase 2 N=375 A Study for the Treatment of Alcohol Dependence
Alcohol Dependence
Primary: Percentage of Heavy Drinking Days at Week 16 Endpoint — -43.02; -38.72 percentage of days — p=0.120
Phase 2 N=162 Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age
Asthma
Primary: Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period — 2.36; 2.39; 2.40; 2.42 Liters…
Phase 2 N=22 TKI258 for Metastatic Inflammatory Breast Cancer Patients
Breast Cancer
Primary: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants — 0; 0; 1 participants